HyunJin Park1, Jin Seo2, Young Han Lee2, Ho-Taek Song*2, Chang Hoon Moon3, Hee-Soon Lee3, Ho Yong Lee3, Hee-Jung Cha4, Young Joo Min3
1Brain Korea 21 Project for Medical Science, Yonsei University, Seoul, Korea, Republic of; 2College of Medicine, Yonsei University, Seoul, Korea, Republic of; 3Biomedical Research Center, Ulsan University Hospital, Korea, Republic of; 4Department of Pathology, Ulsan University Hospital, Korea, Republic of
Dynamic contrast enhanced MRI (DCE-MRI) technique can provides quantitative information about the tumor vasculature and it has been widely used to evaluate the biological activity of targeted therapy in clinical trials. However, there has been little known about the quantitative imaging validation of proteasome activity driven by vascular disrupting agent (VDA) in a cancer model by MRI. Therefore, we investigated antivascular effects of VDA in CT26 colon cancer xenograft mouse model following treatment with the KML001 by DCE-MRI. Significant decrease (p<0.05) of Kep was observed in post treatment of KML001.